Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Method of Patients With Refractory and Relapsed CD-19 Positive Leukemia and Lymphoma Using Academic Anti-CD19 CAR-T Human Cells

NCT07524816 is registered in ClinicalTrials.gov with N.N. Alexandrov National Cancer Centre as lead sponsor.

NCT NCT07524816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Method of Patients With Refractory and Relapsed CD-19 Positive Leukemia and Lymphoma Using Academic Anti-CD19 CAR-T Human Cells
Lead sponsor
N.N. Alexandrov National Cancer Centre
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2021
Completion date
January 1, 2029
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma (lbcl)